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Introduction
The ABO gene is located on the long arm of human chro-
mosome 9 and consists of 7 exons. Exons 6 and 7 encode the 
major proportion including the catalytic domain of the glyco-
syltransferases that mediate the expression of A and B anti-
gens [1, 2]. A number of studies have shown a clear genotype-
phenotype correlation [3–5], and almost 300 gene variants are 
listed in the open access database dbRBC at the NCBI web-
site [6]. Most of the gene variants are characterized by one or 
more SNPs leading to amino acid changes or stop codons. In 
addition, some variants result from nucleotide insertions or 
deletions (INDELs) mostly leading to a frame shift of the 
reading frame and subsequent alteration of the encoded 
amino acid sequence. The ABO blood groups A1, A2, and B 
result from the wild-type allele ABO*A101 and the major 
variant alleles ABO*A201, and ABO*B101. The O pheno-
type is mostly caused by deletional O alleles such as 
ABO*O01 or ABO*O02 each characterized by the INDEL 
polymorphism 261delG in exon 6. The most common non-de-
letional O allele is ABO*O03 with a point mutation in exon 7 
also leading to the O phenotype. Weak expression of A or B 
antigens (Aw, Ax, Ael, Bw, Bx, Bel) is caused by many differ-
ent alleles with mutations distributed over the entire coding 
region of the ABO gene.
Here, we describe a novel ABO gene variant in a patient 
who showed discrepancies in forward and reverse phenotyp-
ing. Depending on the PCR system used, the ABO variant 
also led to discrepant genotyping results. 
Material and Methods
Patient
A 62-year-old woman was hospitalized because of peripheral artery 
occlusive disease. We performed blood group typing because surgical in-
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Summary
Background: Discrepant results in antigen and reverse 
ABO blood typing are often caused by a variant ABO 
gene. Molecular analysis can help to characterize such 
variants. Here, we describe the identification of a novel 
ABO gene variant in a patient with aberrant ABO pheno-
type and discrepant genotyping results. Methods: A pa-
tient with discrepant results in automated forward and 
reverse ABO phenotyping was further investigated by 
serological (gel and tube technique) and molecular (com-
mercial and inhouse PCR-SSP, DNA sequencing) meth-
ods. A PCR-SSP system was established to screen the 
novel mutation in 1,820 blood donors. Results: Standard 
serological tests confirmed blood group O, however, 
only anti-B isoagglutinins were present. A monoclonal 
anti-AB antibody detected very weak agglutination in gel 
technique. Standard ABO genotyping using PCR-SSP led 
to discrepant results (O1/O1 or O1/A) depending on the 
test system used. ABO exon re-sequencing identified a 
novel missense mutation in exon 6 at position 248A>G 
(Asp83Gly) in the binding region of PCR-SSP primers for 
the detection of 261G alleles. Blood donors with regular 
ABO blood groups were all negative for the 248G allele 
designated Aw34. Conclusion: The novel ABO gene vari-
ant Aw34 is associated with very weak A antigen expres-
sion and absent anti-A isoagglutinins. The mutation is 
located in exon 6 close to the O1-specific 261G deletion 
in the binding region of PCR-SSP primers. Presumably, 
depending on the primer concentration used in commer-
cial ABO genotyping kits, the mutation could lead to a 
false-negative reaction.
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delberg University, Medical Faculty Mannheim. Another cohort of 480 
blood donors was collected by the Institute of Transfusion Medicine and 
Immunohematology Magdeburg from a similar geographical region as the 
present case. These donors also had regular ABO blood groups: 228 A 
(47.5%), 179 O (37.3%), 72 B (15.0%), 1 AB (0.2%).
Serologic ABO Blood Grouping
Routine ABO blood typing was performed on the Galileo automated 
system (Immucor GmbH, Rödermark, Germany) using monoclonal rea-
gents for antigen typing and A1, A2, B and O red cells for reverse typing. 
The aberrant phenotype was confirmed in column agglutination testing 
(CAT; ADK Cassette and Reverse Diluent Cassette; Ortho GmbH, 
Neckargemünd, Germany; and ID-Card Diaclon AB0/Rh for patients, 
ID-Card Diaclon AB0/Rh for newborns; Bio-Rad Laboratories GmbH 
München, Germany) and tube technique (immuClone; Immucor). All 
testing sera included monoclonal antibodies (table 1). A polyclonal anti-
A serum was not available.
tervention was planned for the patient. The tests showed discrepant re-
sults in antigen typing (blood group O) on the one hand and in reverse 
blood group typing (blood group A) on the other hand. As there was no 
massive transfusion or blood stem cell transplantation in the patient’s 
medical history, further serological diagnostic and molecular tests had to 
be followed.
DNA Samples of Blood Donors
The geographical origin of blood donors of our transfusion service is 
the southwestern part of Germany. A DNA bank was established as a 
representative sample of our blood donor cohort and encompasses 1,340 
blood donors with a mean age of 46.8 ± 15.3 years (range 18.0–68.8 years) 
and 1:1 gender distribution [7]. Data about ABO blood groups were 
taken from the blood donor files. All donors had regular ABO blood 
groups: 555 A (41.4%), 525 O (39.2%), 177 B (13.2%), 83 AB (6.2%). 
Donors gave written consent to provide blood samples for research pur-
poses. This DNA bank was approved by the ethics committee of the Hei-
Test Anti-A (clone) Anti-AB (clone)
Microplate test (Galileo) Birma-1 -
ADK Cassette anti-AB01 -
ID-Card Diaclon AB0/Rh  
  for patients
A5 ES 131 (ES-15) + Birma-1 + ES-4
ID-Card Diaclon AB0/Rh  
  for newborns
LM 297/628 (LA-2) ES 131 (ES-15) + Birma-1 + ES-4
Tube technique (immuClone) Birma-1 -
Table 1 . Tests and sera used in serological 
ABO typing.
Target Primer binding 
region
Direction Sequence (5’–3’)
Exon amplification
Exon 1 exon 1 
intron 1
sense  
antisense
CCGTCCCTTCCTAGCAGG 
GTGCTGAAAATAGCAGCTCATGG
Exon 2–5 intron 1 
exon 6
sense 
antisense
GGACCATCTTGGCAGATGAAGG 
GCTCGTTGAGGATGTCGATGTTGA
Exon 6 intron 5 
intron 6
sense 
antisense
GATTTGCCCGGTTGGAGTCG 
GCTGCATGAATGACCTTTCCC
Exon 7 intron 6 
exon 7
sense 
antisense
TCGCTGGGAAGAGGATGAAG 
GCCTAGGCTTCAGTTACTCACAACAG
Sequencing
Exon 1 exon 1 
intron 1
sense 
antisense
GTGTTCGGCCTCGGGAAG 
CTGAAGCCTCGCAGCCCTG
Exon 2 intron 1 
intron 2
sense 
antisense
GGGTGTGATGCCTGAATTAC 
CCTTAGGACCCTGATAACTG
Exon 3 intron 2 
intron 3
sense 
antisense
CCTTGCAGCTTCACCGGGAACTC 
AGGCTGACTCCAGAGGTATC
Exon 4 intron 3 
intron 4
sense 
antisense
CATCGCCACAGTGATGGTTGTTC 
ACTGAAGCTCCAGCTCCATC
Exon 5 intron 4 
intron 5
sense 
antisense
CCCTGCTTACCTGCATCCC 
CCCCAACTGAGATTTACATC
Exon 6 intron 5 
intron 6
sense 
antisense
TCGCATTTGCCTCTGGTTGG 
CTACCCTCTGGGAGGACAAG
Exon 7 
(part I)
intron 6 
exon 7
sense 
antisense
CTGCTCTAAGCCTTCCAATG 
AGTAGAAATCGCCCTCGTCC
Exon 7 
(part II)
exon 7 
exon 7
sense 
antisense
AAGGAAACAGAGTTTACCCG 
GAGGTGGATTACCTGGTGTG
Table 2. Primers for amplification and 
sequencing of ABO exons 1–7.
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DNA Isolation and ABO Genotyping
DNA was isolated from EDTA-anticoagulated blood using a commer-
cial system (QIAamp Blood DNA Mini Kit; Qiagen, Hilden, Germany). 
ABO blood group genotyping was performed using PCR with sequence-
specific primers (PCR-SSP) by two commercial kits (ABO-SSP; Inno-
Train Diagnostik GmbH, Kronberg, Germany; and ABO-Type variant; 
BAG Healthcare, Lich, Germany) and an inhouse system. For the in-
house PCR-SSP the ABO gene polymorphisms 261delG (for deletional 
O1 alleles), 802G>A (for the nondeletional O allele O03), 803G>C (for B 
alleles), and 1061delC (for A2 alleles) were analyzed as described previ-
ously [8]. The alleles were detected by 8 separate reactions each with al-
lele-specific and internal control primers. The sizes of PCR products in all 
three systems were very similar, indicating the use of similar if not identi-
cal primers for allele-specific amplification. For further analysis of ABO 
alleles we applied another commercial PCR-SSP kit (ABO-Subtype; 
Inno-Train Diagnostik GmbH).
For genomic DNA sequencing ABO exons 1–7 and flanking intron re-
gions were amplified using primers listed in table 2. Sequence data were 
compared to ABO alleles listed in the RBC database [6]. A PCR-SSP sys-
tem was established for rapid identification of the new 248A>G mutation 
in exon 6 of the ABO gene. Primers for detection of the 248A>G muta-
tion were: 248A-forward 5'-ctccatgtgcagtaggaagga-3'; 248G-forward 5'-tc-
catgtgcagtaggaaggg-3'; 248AG-reverse 5'-cttgatggcaaacacagttaac-3'. The 
system was also validated for screening of DNA samples in pools of up to 
7 samples.
Results
Automated and CAT-based ABO blood group antigen 
typing of the patient showed absence of A and B antigen indi-
cating blood group O (fig. 1A). However, reverse typing using 
A1, A2 and B test cells only showed agglutination of B cells in 
the automated system. In CAT and tube technique anti-A1 
and anti-A2 reactions were also negative (fig. 1B). When 
using a monoclonal anti-AB antibody, we could see very weak 
agglutination in CAT (fig. 1C). The absence of anti-A isoag-
glutinins could indicate a variant ABO allele that leads to 
Fig. 1. Results from 
A forward and B re-
verse ABO typing of 
the patient using the 
gel technique. A and 
B antigens were 
clearly absent in anti-
gen typing. Reverse 
typing failed to detect 
anti-A1 or anti-A2 
isoagglutinins in the 
patient’s serum. Anti-
B isoagglutinins were 
normal (4+). C Anti-
gen typing using fur-
ther monoclonal rea-
gents including an 
anti-AB monoclonal 
antibody led to very 
weak agglutination 
reaction detectable 
by a faint smear of 
erys in the gel.
Fig. 2. Results from ABO genotyping using different PCR-SSP systems. 
A ABO-Type (BAG Healthcare) indicated genotype O1/O1; B ABO-SSP 
(Inno-Train Diagnostik GmbH) and C inhouse system both indicated 
genotype O1/A. The discrepancy resulted from the second reaction 
(nonO1) specific for the detection of 261G. The PCR products of internal 
controls are indicated by arrowheads. Note the weaker PCR band in the 
nonO1 reaction of the inhouse system.
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addition we found a heterozygosity at position 248 in exon 6 
(fig. 3). From the PCR-SSP results shown in figure 2 we have 
clear evidence for the trans constellation of the 248A>G muta-
tion to 261delG of the O1 allele. The nonO1(261G)-specific 
reaction (lane 2) is cleary affected by the mutation, whereas 
the O1(261delG)-specific reaction (lane 1) is not. The muta-
tion has to be in cis to the 261G nucleotide and affects binding 
of the 261G-specific primer. Consequentially, the mutation is 
in trans to the 261delG mutation and binding of the 261delG-
specific primer is not affected. The 248A>G mutation is pre-
sumably located on an A-allele and leads to an amino acid 
change Asp83Gly in the encoded glycosyltransferase. The 
novel variant was deposited in Genbank (JX519570) and des-
ignated Aw34 in the dbRBC. 
In order to estimate the frequency of the 248A>G variant 
we screened 1,340 blood donors with regular ABO blood 
groups from southwestern Germany and 480 blood donors 
from the patient’s geographical origin by using PCR-SSP and 
pooled DNA samples. None of the samples was positive for 
the Aw34 allele (fig. 4).
Discussion
In the present case we describe a novel ABO gene variant 
associated with an aberrant ABO phenotype. In routine-
based (automated) blood typing we found blood group O, but 
absence of anti-A isoagglutinins (normal anti-B). By using 
more sensitive gel techniques and a monoclonal anti-AB anti-
body a very weak agglutination was seen. Thus, the novel 
gene variant was classified as an Aweak allele and designated 
Aw34. Discrepancies between antigen typing and reverse typ-
ing could be a good hint for a variant ABO gene and often 
lead to the identification of novel ABO gene variants [9, 10].
The novel ABO gene variant results from a single base ex-
change (248A>G) in exon 6 introducing glycine instead of as-
partate at amino acid position 83 (D83G) of the ABO glyco-
syltransferase. The two amino acids have very different prop-
very low levels of A-antigens, almost non-detectable by stand-
ard agglutination tests. 
This prompted us to perform ABO genotyping using a 
commercial PCR-SSP kit (fig. 2A). We found a homozygous 
O1 genotype indicating a regular blood group O. This did not 
confirm the postulated A variant and could not explain the 
absence of anti-A isoagglutinins. The second commercial kit 
and our inhouse PCR-SSP system revealed a heterozygous 
O1/A genotype (fig. 2B and 2C). Remarkably, using our in-
house system the PCR band in the non-O1 reaction was 
weaker compared to the O1 reaction. This emphasized our hy-
pothesis of a variant A-allele, however, PCR-SSP analysis of 
several common ABO variants was negative (data not shown).
ABO exon re-sequencing confirmed the heterozygous O1/A 
genotype because of heterozygous 261G deletion in exon 6. In 
Fig. 4. Genotyping of the 248A>G mutation by PCR-SSP. A The 248G-
specific reaction was positive (144 bp) in the patient sample (1) but nega-
tive in donors with regular ABO phenotype (2–5). B Representative re-
sult of screening for the 248A>G mutation in blood donors by PCR-SSP. 
For efficient screening we pooled 7 DNA samples and tested 260 pools. 
As a positive control (+) we pooled the patient DNA carrying the 
248A>G mutation with 6 negative DNAs. The PCR products of internal 
controls are indicated by arrowheads. None of the pools were positive for 
the 248G allele (shown for pools 1–12). 
Fig. 3. Sequence analysis of ABO exon 6 in 
the patient’s DNA. Heterozygosities were seen 
at position 248A>G (novel variant) and 
261G>del (O1 allele). The dashed line indicates 
the binding region of the forward PCR-SSP 
primer specific for the O1 (261del) and the 
nonO1 alleles (261G). 
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kit (BAG Healthcare) and the highest in the ABO-SSP kit 
(Inno-Train Diagnostik GmbH). Our inhouse system could 
have an intermediate concentration (0.5 mmol/l each) of the 
allele-specific forward and reverse primers. This could explain 
the different results of the 261G-specific (nonO1) reactions: 
negative in the ABO-Type kit; regular positive in the ABO-
SSP kit; alleviated positive in the inhouse system.
Based on our results on the screening for the Aw34 allele 
in 1,820 German blood donors, we suggest that the variant al-
lele is very rare if not a private mutation in the patient’s fam-
ily. However, the characterization of the patient’s blood group 
was important for further transfusions and blood group diag-
nostics. Despite the absence of anti-A isoagglutinins, transfu-
sion of blood group O red blood cell concentrates is recom-
mended in such cases because immunization against A anti-
gens cannot be fully excluded. On the other hand, as blood 
donors the carriers of such ABO variants should be classified 
blood group A since residual A antigens could lead to immu-
nological reaction in recipients with anti-A isoagglutinins. In 
summary, the identification of ABO gene variants associated 
with ABO subgroups is an important contribution in each in-
dividual case and also adds knowledge to the current under-
standing of genetic factors that influence blood groups.
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erties and significant effects on the encoded protein are ex-
pected. The same amino acid is altered by the 247G>T 
mutation (D83Y) of the B304 allele identified in one individ-
ual with the B3 phenotype [11]. Two mutations in close prox-
imity, 266C>T (P89L) and 268T>C (W90R), were identified 
as the A210 and A211 alleles, respectively, in Chinese indi-
viduals with A2 phenotype. Furthermore, the 278C>T variant 
(Bw12) leads to the amino acid exchange P93L and is respon-
sible for a Bw phenotype [12]. From our findings with regard 
to the D83G mutation and from phenotypes described for 
other alleles we assume that the protein region 83–93 is essen-
tial for the glycosyltransferase enzymatic activity and could 
cause a weak expression or absence of A or B antigens. 
In our case the mutation 248A>G is located close to the 
261G nucleotide while the 261delG mutation is located in 
trans. The 261G deletion is the most frequent molecular basis 
for the O phenotype (59 alleles currently listed in dbRBC). 
Two commercial and our inhouse PCR-SSP systems for ABO 
genotyping detect the 261G deletion in the O1-specific reac-
tion and 261G in the nonO1-specific reaction [8]. From the 
PCR product sizes (130 bp in all systems) we assume that the 
primers used in the three systems are very similar if not iden-
tical. The 248A>G mutation is located in the binding region 
of the 261G-specific primer in all three PCR-SSP systems. 
The reason for the discrepant genotyping results could be dif-
ferences in PCR buffer composition (i.e. Mg2+ concentration) 
and primer concentrations that is very crucial for the sensitiv-
ity and specificity of PCR-SSP [13]. It could be speculated 
that the primer concentration is the lowest in the ABO-Type 
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